论文部分内容阅读
1型糖尿病是由于胰岛β细胞选择性破坏,而引起机体内胰岛素分泌绝对缺乏的一种自身免疫性疾病。肠促胰岛素在2型糖尿病的临床治疗中已经得到证实,但在1型糖尿病的临床应用仍有待评估,胰高血糖素样肽1(GLP-1)通过促进胰岛β细胞分泌胰岛素、抑制胰腺α细胞的胰高血糖素分泌、间接延缓胃排空和降低患者食欲来降低血糖水平,并且LP-1对胰岛β细胞有一定的保护作用。运用肠促胰岛素治疗非肥胖性糖尿病小鼠的研究中证实肠促胰岛素有免疫调节、抗炎性反应及促进胰岛β细胞再生能力,因此极有可能运用肠促胰岛素延缓1型糖尿病发病、阻止病情进展恶化、部分恢复胰岛β细胞分泌胰岛素能力。
Type 1 diabetes is an autoimmune disease that causes an absolute lack of insulin secretion in the body due to the selective destruction of islet beta cells. Insulinotropic hormone has been demonstrated in the clinical treatment of type 2 diabetes, but its clinical use in type 1 diabetes remains to be evaluated. Glucagon-like peptide 1 (GLP-1) inhibits pancreatic alpha by promoting the secretion of insulin by pancreatic beta cells Glucagon secretion from cells indirectly delays gastric emptying and reduces appetite in patients to lower blood glucose levels, and LP-1 has a protective effect on pancreatic β-cells. The use of incretin therapy in non-obese diabetic mice confirms that incretin has immunomodulatory, anti-inflammatory responses and promotes pancreatic beta-cell regeneration and is therefore likely to use incretin to delay the onset of type 1 diabetes and prevent its progression Progress is deteriorating, partially restoring islet β-cell insulin secretion.